Korro Bio, Inc. (KRRO)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Collaboration revenue | 1,460 | 2,550 | ||
| Research and development | 21,031 | 19,739 | ||
| General and administrative | 7,631 | 7,831 | ||
| Total operating expenses | 28,662 | 27,570 | ||
| Loss from operations | -27,202 | -25,020 | ||
| Other income, net | 1,433 | 1,633 | ||
| Total other income, net | 1,433 | 1,633 | ||
| Loss before provision for income taxes | -25,769 | -23,387 | ||
| Provision for income taxes | 1 | - | ||
| Net loss | -25,770 | -23,387 | ||
| Foreign currency translation adjustments, net | 13 | 1 | ||
| Unrealized (loss) gain on available-for-sale marketable securities | -74 | -3 | ||
| Comprehensive loss | -25,857 | -23,391 | ||
| Net loss per share, basic | -2.74 | -2.49 | ||
| Net loss per share, diluted | -2.74 | -2.49 | ||
| Weighted average number of shares outstanding, basic | 9,390,542 | 9,384,266 | ||
| Weighted average number of shares outstanding, diluted | 9,390,542 | 9,384,266 | ||